Mrs. Dorothy Eunice Boardman-blocker, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 194 Bear Mill Rd, Crawford, GA 30630 Phone: 706-614-5923 Fax: 706-383-7524 |
News Archive
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
Henry Schein, Inc., the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended September 24, 2011.
Friday, January 8, 2010, the Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab), a new biologic response modifier for adult patients with moderately to severely active rheumatoid arthritis (RA).
A major new research program supported by the Innovative Medicines Initiative launches today, which will develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology.
FINDINGS : Researchers found that Tai Chi, a traditional Chinese low-impact mind-body exercise, provided significant health benefits for adults suffering from tension headaches
› Verified 8 days ago